Profile of:

Philip Mease

Philip J. Mease is Director of Rheumatology Research at the Swedish Medical Center/Providence St. Joseph Health and Clinical Professor at the University of Washington School of Medicine in Seattle, WA, USA. His clinical practice is based at Seattle Rheumatology Associates. Dr Mease earned his undergraduate and medical degrees at Stanford University (Stanford, CA, USA). He then completed his residency in internal medicine and a fellowship in rheumatology at the University of Washington School of Medicine. Dr Mease’s research interests include psoriatic arthritis (PsA) and spondyloarthritis (SpA), rheumatoid arthritis (RA), osteoarthritis (OA), fibromyalgia (FM), and osteoporosis. His research focuses on disease state, outcome measure development, and determining the efficacy and safety of emerging therapies for these conditions. His seminal 2000 Lancet paper established the efficacy of anti-tumour necrosis factor (TNF) therapy in PsA. He has authored over 550 journal articles and many hundreds of abstracts, book chapters, and edited textbooks on PsA and axial SpA (AxSpA). Dr Mease is a prolific international speaker at academic congresses, grand rounds, and other educational activities for rheumatologists and dermatologists, and is considered an international key opinion leader, researcher, educator, and clinician regarding SpA, including PsA, ankylosing spondylitis (AS), and non-radiographic SpA. He is a reviewer for multiple journals including New England Journal of Medicine, Lancet, Arthritis & Rheumatology, Arthritis Care & Research, Annals of the Rheumatic Diseases, The Journal of Rheumatology, and Seminars in Arthritis and Rheumatism. Dr Mease is Past President and Founding Organizer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA); a member of the Assessment of Spondyloarthritis international Society (ASAS), the Spondyloarthritis Research and Treatment Network (SPARTAN), and The Rheumatology Education Group (TREG); and Past President of the Northwest Rheumatism Society. He has also been active in the Outcome Measures in Rheumatology (OMERACT) research organization as Co-Chair of the PsA and chronic pain working groups and as a member of the steering committee. Dr Mease is an active mentor of young investigators in these organizations. He serves in an educational and advisory role for the US Food and Drug Administration (FDA) and is a member of the steering committee of the arthritis section of the International Consortium for Health Outcomes Measurement (ICHOM). He conducts disease state research in registries such as the Consortium of Rheumatology Researchers of North America (CorEvitas/Corrona), for which he is Director of the PsA–SpA arm. Dr Mease is a Master of the American College of Rheumatology (ACR) and has received its Medical Communicator of the Year Award for his teaching there and in the community. He is a Co-Chair of the ACR abstract review committee section on SpA and PsA and serves on the Voting Committee for the ACR-NPF (National Psoriasis Foundation) Psoriatic Arthritis treatment guidelines task force. He is also Co-Chair of the PsA task force of the NPF, which in 2019 awarded him a lifetime achievement award for his work in advancing the field of PsA. Expertscape ranks Dr Mease as the most published worldwide expert in PsA and the 24th most published in AxSpA in the past decade.

Full name: Philip Mease

Current country: United States

Membership level: Full

Type of membership: Member

Number of publications: 3

Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy (2021)

Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis. (2019)

Axial Spondyloarthritis. (2019)